Safety of MOON101 for the Treatment of Peanut Allergy

Study acronym: SURVEYOR
StatusSuspended
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status changed: Active, Not Recruiting → Suspended Sponsor's reason: Clinical Hold
  2. Enrollment closed, study ongoing
    • Eligibility criteria expanded, about 15 words
    • Secondary endpoints: details revised at 4 of 10 entries
    • Site details revised at 5 of 5 sites
  3. Start date changed from estimate of Jun 5, 2026 to Jun 29, 2026
    • Site details revised at 2 of 5 sites
    v7
  4. Site details revised at 1 of 5 sitesv6
  5. Site details revised at 1 of 5 sitesv5
  6. Site contacts updated at 5 of 5 sitesv4
  7. Recruitment opened
    • Start date: May 7, 2026 to Jun 5, 2026
    • Site details revised at 5 of 5 sites
    v3
  8. Re-verified, no change to tracked fieldsv2
  9. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this open-label, single escalating dose study in 3 sequential groups: adults, adolescents, and children with peanut allergy is to assess the safety of MOON101. The main question it aims to answer is: 1. the incidence and frequency of all treatment emergent adverse events (TEAEs) from baseline through study exit. 2. to determine the highest tolerated dose for each participant, as defined by the highest MOON101 dose level administered which did not cause a dose-limiting symptom (DLS). The study will compare MOON101 and placebo. All participants will receive both active MOON101 (peanut allergen) and placebo (no peanut allergen).
Trial Details
NCT Number NCT07580898
Lead Sponsor Moonlight Therapeutics, Inc.
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID)
Conditions
(from sponsor)		 Peanut Allergy
Related terms Peanut Hypersensitivity
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov